Representativeness and adverse event reporting in late-phase clinical trials for rifampin-susceptible tuberculosis: a systematic review.
Saved in:
| Title: | Representativeness and adverse event reporting in late-phase clinical trials for rifampin-susceptible tuberculosis: a systematic review. |
|---|---|
| Authors: | Burman W; Public Health Institute, Denver Health, Denver, CO, USA; Department of Medicine, University of Colorado Anschutz Medical Campus, Denver, CO, USA. Electronic address: bill.burman@dhha.org., Luczynski P; Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Horsburgh CR; Department of Global Health, Department of Epidemiology, and Department of Biostatistics, School of Public Health, Boston University, Boston, MA, USA; Department of Medicine, School of Medicine, Boston University, Boston, MA, USA., Phillips PPJ; Department of Medicine, University of California San Francisco, San Francisco, CA, USA., Johnston J; Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; Provincial TB Services, British Columbia Centre for Disease Control, Vancouver, BC, Canada. |
| Source: | The Lancet. Infectious diseases [Lancet Infect Dis] 2025 Feb; Vol. 25 (2), pp. e86-e98. Date of Electronic Publication: 2024 Nov 26. |
| Publication Type: | Journal Article; Systematic Review; Meta-Analysis |
| Journal Info: | Publisher: Elsevier Science Country of Publication: United States NLM ID: 101130150 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-4457 (Electronic) Linking ISSN: 14733099 NLM ISO Abbreviation: Lancet Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1474-4457 |
|---|---|
| DOI: | 10.1016/S1473-3099(24)00597-8 |
